StockData
Biogen Inc. logo

Biogen Inc. (BIIB) stock

BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3056% above fair value
$250.79−0.86 (-0.34%)

Close on Nov 17, 2026Market cap $37.07BP/E 107.2Yield –

Biogen operating margin

Operating margin is operating income as a percentage of revenue.

Biogen's operating margin for the twelve months ending Mar 31, 2022 was 22.9%. For fiscal 2021 it was 25.9%, against 33.8% the year before. The highest annual figure on record is 49.0% in fiscal 2019.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2021Dec 31, 202125.9%−8.0
FY2020Dec 31, 202033.8%−15.1
FY2019Dec 31, 201949.0%+5.2
FY2018Dec 31, 201843.8%+0.2
FY2017Dec 31, 201743.6%−1.4
FY2016Dec 31, 201645.0%−0.4
FY2015Dec 31, 201545.4%+4.5
FY2014Dec 31, 201440.9%+4.7
FY2013Dec 31, 201336.3%+2.6
FY2012Dec 31, 201233.6%−0.5
FY2011Dec 31, 201134.2%+7.7
FY2010Dec 31, 201026.5%−3.1
FY2009Dec 31, 200929.6%−0.0
FY2008Dec 31, 200829.6%+5.0
FY2007Dec 31, 200724.6%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q1 FY2022Mar 31, 202224.1%−12.0
Q4 FY2021Dec 31, 202121.5%+33.1
Q3 FY2021Sep 30, 202128.6%−3.6
Q2 FY2021Jun 30, 202117.5%−36.1
Q1 FY2021Mar 31, 202136.2%−15.3
Q4 FY2020Dec 31, 2020-11.6%−60.0
Q3 FY2020Sep 30, 202032.2%−18.0
Q2 FY2020Jun 30, 202053.6%−0.4
Q1 FY2020Mar 31, 202051.5%+8.4
Q4 FY2019Dec 31, 201948.4%+7.5
Q3 FY2019Sep 30, 201950.2%+0.8
Q2 FY2019Jun 30, 201954.1%+17.9
Q1 FY2019Mar 31, 201943.1%−6.0
Q4 FY2018Dec 31, 201840.9%−3.4
Q3 FY2018Sep 30, 201849.4%−4.4
Q2 FY2018Jun 30, 201836.1%−2.9
Q1 FY2018Mar 31, 201849.0%+12.6
Q4 FY2017Dec 31, 201744.3%+13.4
Q3 FY2017Sep 30, 201753.7%–
Q2 FY2017Jun 30, 201739.0%–
Q1 FY2017Mar 31, 201736.5%–
Q4 FY2016Dec 31, 201630.9%–

More Biogen figures

See a number that looks wrong?